Statement by Diana Zuckerman at the FDA's meeting on strengthening the Center for Devices and Radiological Health's 501(K) Review Process -

Clearly, the focus of the 510(k) process has been on letting companies change devices in the name of innovation, not based on public health standards or problems. As a result, devices are being sold that are so different from previous “substantially equivalent” devices that the FDA has no idea whether the product is safe or effective, and in many cases these innovative devices are either not as safe as other products on the market, or not as effective. This costs the medical system (and individuals) billions of dollars each year.

Letter to Hon. Andrea M. Boland, Maine House of Representatives, in support of “Children’s Wireless Protection Act,” February 1, 2010 -

The Cancer Prevention and Treatment Fund of the National Research Center for Women & Families strongly supports your pioneering, proactive legislation. The “Children’s Wireless Protection Act” would help protect the health of Maine residents by making the state the first to require warning labels that radiation from cell phones may cause brain cancer.

Statement of Dr. Diana Zuckerman before the DC Committee on Government Operations and the Environment regarding bisphenol A and phthalates, January 20, 2010 -

The Cancer Prevention and Treatment Fund of the National Research Center for Women & Families strongly supports Bill 18-521, the “Human and Environmental Health Protection Amendment Act of 2009,” which will help to ensure that children and residents of the District of Columbia are better protected from the adverse health affects of a variety of chemicals.

Patient and Consumer Coalition letter to Congressional leaders, January 8, 2010 -

The Cancer Prevention and Treatment Fund/National Research Center for Women & Families, as part of the Patient and Consumer Coalition, urges that the House language on comparative effectiveness research be included when the House and Senate health care bills are reconciled. The House language places the center for comparative effectiveness research in the Agency for Healthcare Research and Quality (AHRQ) to minimize industry conflicts-of-interests and ensure scientific objectivity. This will benefit patients by reducing the use of ineffective and potentially dangerous treatments and medical tests.